Effect of DP-1904, a new thromboxane A2 synthetase inhibitor, on guinea pig experimental asthma.
Takami
M
M
Research Institute, Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan.
Takata
Y
Y
Matsumoto
K
K
Ono
S
S
Tsukada
W
W
D015121:6-Ketoprostaglandin F1 alpha / Q000032:analysis / Q000097:blood; D000818:Animals; D000941:Antigens; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D016084:Bronchoconstriction / Q000187:drug effects; D006168:Guinea Pigs; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D066298:In Vitro Techniques; D008168:Lung / Q000187:drug effects / Q000503:physiopathology*; D010047:Ovalbumin; D013764:Tetrahydronaphthalenes / Q000494:pharmacology / Q000627:therapeutic use*; D013929:Thromboxane B2 / Q000032:analysis / Q000097:blood; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D000941:Antigens; D007093:Imidazoles; D013764:Tetrahydronaphthalenes; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D010047:Ovalbumin; C056295:nafagrel; D013930:Thromboxane-A Synthase